We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MKC:NYSEMcCormick & Company, Incorporated Analysis

Data as of 2026-03-13 - not real-time

$58.67

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

McCormick & Co. (MKC) is trading at $58.66, well below its 50‑day SMA of $66.19 and the 200‑day SMA of $68.41, indicating a short‑term downtrend. However, the RSI of 30 suggests the stock is oversold and approaching its near‑term support at $57.29, while the 30‑day volatility of 37% and a low beta of 0.33 point to heightened price swings but limited market correlation. The company delivers a solid dividend yield of 3.35% with a payout ratio of 61%, and fundamentals such as a 14% ROE, 2.9% revenue growth, and a forward PE of 17.45 reinforce its defensive character.
Recent material news includes a scheduled Q1 earnings release on March 31, UBS cutting its price target, and insider sales by a director, which temper optimism. Yet the median analyst price target of $75 implies roughly 28% upside, and the stock’s crossing above its 200‑day moving average hints at a potential longer‑term trend reversal. Overall, the blend of attractive yield, decent profitability, and undervalued technical positioning creates a nuanced investment case.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI near oversold levels (30) indicating possible bounce
  • Price hovering just above key support at $57.29
  • Recent insider selling and UBS target reduction adding downside pressure

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Median analyst target of $75 suggests ~28% upside
  • Strong dividend yield (3.35%) and sustainable payout
  • Fundamental stability: ROE 14%, forward PE 17.45, modest revenue growth

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Defensive consumer sector with low beta (0.33) offering resilience
  • Consistent cash flow generation supporting dividend continuity
  • Elevated debt-to-equity (73%) warrants caution over extended horizons

Key Metrics & Analysis

Financial Health

Revenue Growth2.90%
Profit Margin11.54%
P/E Ratio20.0
ROE14.24%
ROA5.23%
Debt/Equity73.21
P/B Ratio2.7
Op. Cash Flow$962.2M
Free Cash Flow$564.5M

Technical Analysis

TrendNeutral
RSI30.3
Support$57.29
Resistance$72.41
MA 20$66.67
MA 50$66.19
MA 200$68.41
MACDBearish
VolumeDecreasing
Fear & Greed Index73.09

Valuation

Fair Value$17.31
Target Price$73.85
Upside/Downside25.88%
GradeFair
TypeBlend
Dividend Yield3.35%

Risk Assessment

Beta0.33
Volatility37.43%
Sector RiskLow
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.